Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP)

被引：4

作者：

Sakata, Yoshihiko ^{[1
]}

Saito, Go ^{[2
]}

Sakata, Shinya ^{[3
]}

Oya, Yuko ^{[4
,5
]}

Tamiya, Motohiro ^{[6
]}

Suzuki, Hidekazu ^{[7
]}

Shibaki, Ryota ^{[8
]}

Okada, Asuka ^{[9
]}

Yokoyama, Toshihide ^{[10
]}

Matsumoto, Hirotaka ^{[11
]}

Otsuki, Taiichiro ^{[12
]}

Sato, Yuki ^{[13
]}

Junji, Uchida ^{[14
]}

Tsukita, Yoko ^{[15
]}

Inaba, Megumi ^{[16
]}

Ikeda, Hideki ^{[2
,17
]}

Arai, Daisuke ^{[18
]}

Maruyama, Hirotaka ^{[19
]}

Hara, Satoshi ^{[20
]}

Tsumura, Shinsuke ^{[21
]}

Morinaga, Jun ^{[22
]}

Sakagami, Takuro ^{[3
]}

机构：

[1] Saiseikai Kumamoto Hosp, Div Resp Med, 5-3-1 Chikami,Minami Ku, Kumamoto 8614193, Japan

[2] Chiba Univ, Grad Sch Med, Dept Respirol, 1-8-1 Inohana,Chuo Ku, Chiba, Chiba 2608670, Japan

[3] Kumamoto Univ Hosp, Dept Resp Med, 1-1-1 Honjo,Chuo Ku, Kumamoto 8608556, Japan

[4] Aichi Canc Ctr Hosp, Dept Thorac Oncol, 1-1 Kanokoden,Chikusa Ku, Nagoya, Aichi 4648681, Japan

[5] Fujita Hlth Univ, Sch Med, Dept Resp Med, Kutsukake Cho, Toyoake, Aichi 4701192, Japan

[6] Osaka Int Canc Inst, Dept Thorac Oncol, 3-1-69 Otemae,Chuo Ku, Osaka, Osaka 5418567, Japan

[7] Osaka Habikino Med Ctr, Dept Thorac Oncol, 3-7-1 Habikino, Habikino, Osaka 5838588, Japan

[8] Wakayama Med Univ, Internal Med 3, 811-1 Kimiidera, Wakayama, Wakayama 6418509, Japan

[9] Osaka City Gen Hosp, Dept Med Oncol, 2-13-22 Miyakojima Hondori,Miyakojima Ku, Osaka 5340021, Japan

[10] Kurashiki Cent Hosp, Dept Resp Med, 1-1-1 Miwa, Kurashiki, Okayama 7108602, Japan

[11] Hyogo Prefectural Amagasaki Gen Med Ctr, Dept Resp Med, 2-17-77 Higashinaniwa, Amagasaki, Hyogo 6608550, Japan

[12] Hyogo Med Univ, Dept Resp Med & Hematol, Sch Med, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan

[13] Kobe City Med Ctr Gen Hosp, Dept Resp Med, 2-1-1 Minatojimaminami,Chuo Ku, Kobe, Hyogo 6500047, Japan

[14] Natl Hosp Org Osaka Toneyama Med Ctr, Dept Thorac Oncol, 5-1-1 Toneyama, Toyonaka, Osaka 5608552, Japan

[15] Tohoku Univ, Grad Sch Med, Dept Resp Med, 1-1 Seiryo,Aoba Ku, Sendai, Miyagi 9808574, Japan

[16] Kumamoto City Hosp, Div Resp Med, 1-5-1 Tainoshima,Minami Ku, Kumamoto 8620965, Japan

[17] Kimitsu Chuo Hosp, Dept Resp Med, 1010 Sakurai, Kisarazu, Chiba 2928535, Japan

[18] Saiseikai Utsunomiya Hosp, Dept Internal Med, 911-1 Takebayashi, Utsunomiya, Tochigi 3210974, Japan

[19] Kumamoto Rosai Hosp, Dept Resp Med, Japan Org Occupat Hlth & Safety, 1670 Takehara, Yatsushiro, Kumamoto 8668533, Japan

[20] Itami City Hosp, Dept Resp Med, 1-100 Koyaike, Itami, Hyogo 6648540, Japan

[21] Kumamoto Reg Med Ctr, Dept Resp Med, 5-16-10 Honjo,Chuo Ku, Kumamoto 8600811, Japan

[22] Kumamoto Univ Hosp, Dept Clin Invest Biostat, 1-1-1 Honjo,Chuo Ku, Kumamoto 8608556, Japan

来源：

LUNG CANCER | 2023年 / 186卷

关键词：

Non-small cell lung cancer; EGFR mutation; First-line therapy; Osimertinib; Elderly; Real world; FACTOR RECEPTOR MUTATIONS; OPEN-LABEL; PHASE-II; GEFITINIB; CHEMOTHERAPY; MULTICENTER; ERLOTINIB; AFATINIB;

D O I：

10.1016/j.lungcan.2023.107426

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objectives: Osimertinib is the primary treatment for patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer. However, evidence of the outcomes of osimertinib treatment in patients over 75 years of age in the real-world setting is limited.Materials and Methods: This retrospective study analyzed the data of 538 patients (203 elderly and 335 non -elderly) with EGFR mutation-positive lung cancer in whom osimertinib was initiated as first-line treatment between August 2018 and December 2019. Patients over 75 years of age were classified as elderly. The data cut-off date was February 28, 2022.Results: The progression-free survival (PFS) did not significantly differ between the elderly and non-elderly groups [elderly group: median PFS, 16.9 months (95 % confidence interval (CI), 14.3-20.2); non-elderly group: median PFS, 22.1 months (95 % CI: 19.5-26.3); hazard ratio (HR) for the elderly against the non -elderly: 1.21 (95 % CI: 0.98-1.50), p = 0.079]. However, the time to treatment failure (TTF) was significantly shorter in the elderly than in the non-elderly [elderly group: median TTF, 14.0 months (95 % CI: 0.98-1.50); non -elderly group: median TTF, 21.8 months (95 % CI: 18.2-24.6); HR for the elderly against the non-elderly: 1.46 (95 % CI: 1.20-1.77), p < 0.001]. Furthermore, the rate of treatment discontinuation because of adverse events was 28.6 % in the elderly and 14.9 % in the non-elderly (p < 0.001). Among patients who discontinued treat-ment, the conversion rate to second-line treatment was 39.6 % in the elderly and 72.8 % in the non-elderly. In addition, the median overall survival was 30 months (95 % CI: 25.8-37.7) in the elderly and not reached (NR) (95 % CI: NR-NR) in the non-elderly (p < 0.001).Conclusion: In a real-world clinical setting, elderly patients receiving osimertinib as first-line treatment should be aware of the frequent inability to transition to second-line treatment due to adverse events.

引用

页数：10

共 50 条

[1] Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT)
Sakata, Yoshihiko
Sakata, Shinya
Oya, Yuko
Tamiya, Motohiro
Suzuki, Hidekazu
Shibaki, Ryota
Okada, Asuka
Kobe, Hiroshi
Matsumoto, Hirotaka
Yokoi, Takashi
Sato, Yuki
Uenami, Takeshi
Saito, Go
Tsukita, Yoko
Inaba, Megumi
Ikeda, Hideki
Arai, Daisuke
Maruyama, Hirotaka
Hara, Satoshi
Tsumura, Shinsuke
Morinaga, Jun
Sakagami, Takuro
EUROPEAN JOURNAL OF CANCER, 2021, 159 : 144 - 153
[2] Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea
Lee, Sung Yong
Choi, Chang-Min
Chang, Yoon Soo
Lee, Kye Young
Kim, Seung Joon
Yang, Sei Hoon
Ryu, Jeong Seon
Lee, Jeong Eun
Lee, Shin Yup
Park, Ji Young
Kim, Young-Chul
Oh, In-Jae
Jung, Chi Young
Lee, Sang Hoon
Yoon, Seong Hoon
Choi, Juwhan
Jang, Tae Won
TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (12) : 4353 - +
[3] First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting
Park, Keunchil
Lim, Darren Wan-Teck
Okamoto, Isamu
Yang, James Chih-Hsin
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
[4] Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
Ramalingam, Suresh S.
Yang, James C-H
Lee, Chee Khoon
Kurata, Takayasu
Kim, Dong-Wan
John, Thomas
Nogami, Naoyuki
Ohe, Yuichiro
Mann, Helen
Rukazenkov, Yuri
Ghiorghiu, Serban
Stetson, Daniel
Markovets, Aleksandra
Barrett, J. Carl
Thress, Kenneth S.
Janne, Pasi A.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (09) : 841 - +
[5] Retrospective analysis of independent predictors of progression-free survival in patients with EGFR mutation-positive advanced non-small cell lung cancer receiving first-line osimertinib
Teranishi, Shuhei
Sugimoto, Chihiro
Nagaoka, Satoshi
Nagayama, Hirokazu
Segawa, Wataru
Miyasaka, Atsushi
Hiro, Shuntaro
Kajita, Yukihito
Maeda, Chihiro
Kobayashi, Nobuaki
Yamamoto, Masaki
Kudo, Makoto
Kaneko, Takeshi
THORACIC CANCER, 2022, 13 (19) : 2741 - 2750
[6] First-line osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status
Takamizawa, Shigemasa
Okuma, Yusuke
Kato, Yasuhiro
Hakozaki, Taiki
Kitagawa, Shingo
Zenke, Yoshitaka
FUTURE ONCOLOGY, 2021, 18 (03) : 291 - 300
[7] First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study
Igawa, Satoshi
Fukui, Tomoya
Kasajima, Masashi
Ono, Taihei
Ozawa, Takahiro
Kakegawa, Mikiko
Kusuhara, Seiichiro
Sato, Takashi
Nakahara, Yoshiro
Hisashi, Mitsufuji
Sasaki, Jiichiro
Naoki, Katsuhiko
INVESTIGATIONAL NEW DRUGS, 2022, 40 (02) : 430 - 437
[8] Dacomitinib as first-line treatment for EGFR mutation-positive non-small cell lung cancer
Reungwetwattana, Thanyanan
Rohatgi, Nitesh
Mok, Tony S.
Prabhash, Kumar
EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (03): : 161 - 171
[9] First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study
Lorenzi, Martina
Ferro, Alessandra
Cecere, Fabiana
Scattolin, Daniela
Del Conte, Alessandro
Follador, Alessandro
Pilotto, Sara
Polo, Valentina
Santarpia, Mariacarmela
Chiari, Rita
Pavan, Alberto
Dal Maso, Alessandro
Da Ros, Valentina
Targato, Giada
Vari, Sabrina
Indraccolo, Stefano
Calabrese, Fiorella
Frega, Stefano
Bonanno, Laura
Conte, Pier Franco
Guarneri, Valentina
Pasello, Giulia
ONCOLOGIST, 2022, 27 (02) : 87 - E115
[10] Osimertinib in the Treatment of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
Pan, Jie
Cai, Xiaoping
Cao, Zhuo
Pan, Jiongwei
Zheng, Hao
PHARMACOLOGY, 2023, 108 (01) : 8 - 16

← 1 2 3 4 5 →